reboxetine has been researched along with dinoprostone in 2 studies
| Studies (reboxetine) | Trials (reboxetine) | Recent Studies (post-2010) (reboxetine) | Studies (dinoprostone) | Trials (dinoprostone) | Recent Studies (post-2010) (dinoprostone) |
|---|---|---|---|---|---|
| 626 | 193 | 184 | 29,105 | 1,346 | 6,357 |
| Protein | Taxonomy | reboxetine (IC50) | dinoprostone (IC50) |
|---|---|---|---|
| Prostaglandin E2 receptor EP1 subtype | Homo sapiens (human) | 0.0155 | |
| Prostaglandin E2 receptor EP4 subtype | Homo sapiens (human) | 0.0031 | |
| Prostaglandin E2 receptor EP4 subtype | Rattus norvegicus (Norway rat) | 0.0021 | |
| Prostaglandin E2 receptor EP3 subtype | Homo sapiens (human) | 0.002 | |
| Prostaglandin E2 receptor EP2 subtype | Homo sapiens (human) | 0.0087 | |
| Prostacyclin receptor | Homo sapiens (human) | 0.26 | |
| Prostaglandin E2 receptor EP2 subtype | Rattus norvegicus (Norway rat) | 0.0052 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arolt, V; Cerovecki, A; Dehning, S; Douhe, A; Goldstein-Müller, B; Hetzel, G; Kleindienst, N; Maino, K; Möller, HJ; Müller, N; Riedel, M; Schwarz, MJ; Spellmann, I | 1 |
| Duarte, ID; Guzzo, LS; Resende, LC; Romero, TR | 1 |
1 trial(s) available for reboxetine and dinoprostone
| Article | Year |
|---|---|
The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine.
Topics: Adrenergic Uptake Inhibitors; Adult; Anti-Anxiety Agents; Antidepressive Agents; Celecoxib; Cyclooxygenase 2 Inhibitors; Depressive Disorder; Dinoprostone; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Inflammation; Interleukin-6; Lorazepam; Male; Middle Aged; Morpholines; Patient Dropouts; Pilot Projects; Psychological Tests; Pyrazoles; Reboxetine; Serotonin; Severity of Illness Index; Sulfonamides | 2006 |
1 other study(ies) available for reboxetine and dinoprostone
| Article | Year |
|---|---|
CB1 and CB2 cannabinoid receptor agonists induce peripheral antinociception by activation of the endogenous noradrenergic system.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-2 Receptor Antagonists; Adrenergic beta-Antagonists; Adrenergic Uptake Inhibitors; Amides; Analgesics; Animals; Arachidonic Acids; Cannabinoid Receptor Agonists; Dinoprostone; Endocannabinoids; Ethanolamines; Male; Morpholines; Norepinephrine; Pain Measurement; Palmitic Acids; Peripheral Nerves; Polyunsaturated Alkamides; Prazosin; Propranolol; Rats; Rats, Wistar; Reboxetine; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Sympathetic Nervous System; Yohimbine | 2013 |